ChemImage v. Ethicon Lawsuit: $76.6M Ruling and Settlement

The ChemImage Ethicon lawsuit ended with a federal judge finding that Ethicon, a Johnson & Johnson subsidiary, improperly terminated a multimillion-dollar development contract with Pittsburgh biotech ChemImage Corporation. On July 8, 2025, the U.S. District Court for the Southern District of New York entered judgment of $76,559,521 against Ethicon.¹²³

The Deal Behind the Dispute

ChemImage, founded in Pittsburgh by Patrick Treado, built AI-driven molecular chemical imaging technology intended to give surgeons real-time visibility into tumors, veins, arteries, and bile ducts during operations.⁴

On December 27, 2019, ChemImage and Ethicon signed a 104-page Research, Development, License and Commercialization Agreement pairing ChemImage’s imaging software with Ethicon’s robotic surgery hardware. The internal program was called “Project Erie” and covered two technologies: EndoVere, for revealing anatomical structures and tumors during surgery, and LightSphere, a diagnostic tool for detecting cancerous and pre-cancerous tissue.⁵

Ethicon paid $7 million upfront, with up to $149 million in milestone payments and royalty potential of up to $1.5 billion.⁶ The contract created a Joint Steering Committee with two representatives from each company, and decisions on the development plan and milestone achievement required a unanimous JSC vote.⁵

Two termination paths mattered. A “for cause” termination — based on a material breach such as a missed milestone — let Ethicon keep certain intellectual property rights. A “without cause” termination required 120 days’ notice, a $40 million non-refundable termination fee, and the return of rights to ChemImage’s IP.⁵⁷

Why Ethicon Terminated, and What It Cost ChemImage

On March 6, 2023, Ethicon sent a termination letter invoking the “for cause” clause. It claimed ChemImage had failed the “VAB” component of Milestone 1B, tied to identifying veins, arteries, and bile ducts.¹⁵

The effect on ChemImage was immediate. The company employed roughly 75 people at its Point Breeze offices in Pittsburgh. Within two months of the termination, it laid off its entire staff and shut down.⁸ Because Ethicon had classified the termination as “for cause,” it retained an exclusive license to ChemImage’s core IP, which kept ChemImage from bringing in a new partner to keep the technology alive.⁵

ChemImage sued Ethicon and Johnson & Johnson in April 2024 in the Southern District of New York, Case No. 1:24-cv-02646. The complaint brought five counts, including breach of contract against Ethicon and tortious interference against J&J. Initial damages sought exceeded $1.5 billion.⁴⁶ ChemImage also argued that the real driver was J&J’s broader retreat from surgical robotics, pointing to a separate layoff of 350 employees in J&J’s robotics program.

What the Court Found

A two-week bench trial before U.S. District Judge Jesse M. Furman began on March 17, 2025.⁶ Judge Furman issued his Findings of Fact and Conclusions of Law on May 30, 2025. The decisive question was procedural: had Ethicon followed the contract’s required steps before terminating for cause?

The court concluded it had not. The agreement gave the Joint Steering Committee — not Ethicon acting alone — the authority to decide whether a milestone had been met. Ethicon never convened a JSC vote on the VAB milestone. The court found that Ethicon officials had internally decided to end the project by February 10, 2023, but continued a question-and-answer exchange with ChemImage about the VAB milestone report as if evaluation were ongoing.⁹

Ethicon cancelled a formal JSC meeting scheduled for February 28, 2023 that had the VAB milestone on the agenda, converting it into a brief “touchpoint” without substantive discussion. Ethicon representatives then declined to attend the final scheduled JSC meeting on March 7, 2023, a day after issuing the termination letter.⁹

Judge Furman wrote that “where the contract specifies conditions precedent to the right of cancellation, the conditions must be complied with,” and held that Ethicon “could not cut corners” by bypassing the JSC process.⁵⁹

Johnson & Johnson Was Not Held Liable

Although Ethicon lost on the breach claim, parent company Johnson & Johnson was found not liable for tortious interference. The court also rejected or declined to reach ChemImage’s other breach theories beyond the JSC-bypass finding.⁵

How the $76.6 Million Was Calculated

Because the “for cause” termination was improper, the court treated it as a “without cause” termination. That triggered the contract’s $40 million non-refundable termination fee, with statutory interest running from July 4, 2023.⁹

The court added roughly $36.6 million in IP impairment damages to compensate for harm done to ChemImage’s technology portfolio while Ethicon’s “for cause” designation locked up its IP. The court applied a 17% discount rate proposed by ChemImage and rejected Ethicon’s proposed 40% rate. A $510,000 deduction was taken for proceeds from ChemImage’s asset sales.¹⁰¹

The total judgment entered July 8, 2025 came to $76,559,521.¹¹⁰¹¹

The award would have been far larger, but the agreement’s damages limitation clause barred consequential, punitive, and lost-profit damages, confining recovery to direct damages. That is why ChemImage recovered tens of millions rather than the $1.5 billion it originally sought.⁵

The December 2025 Settlement

Ethicon signaled it was weighing an appeal. Before that path played out, Johnson & Johnson and ChemImage reached a settlement in December 2025 resolving the dispute. The financial terms were not publicly disclosed.²³¹¹

The settlement does not restore the business it was fought over. ChemImage closed in May 2023 after losing its sole commercial partner and has not reopened.⁸

1
MassDevice. Judge Ethicon $76M ChemImage Failed Partnership
2
Law360. J&J ChemImage Reach Deal After $77M AI Patent Judgment
3
IIPLA. J&J and ChemImage Settle Dispute After $77M AI Patent Verdict
4
Pittsburgh Post-Gazette. Pittsburgh Biotech Tumors Johnson Ethicon ChemImage
5
Midpage. ChemImage Corporation v. Johnson & Johnson
6
Business Insider. AI Imaging Firm Johnson and Johnson Stole Tech Trial
7
Case Law Vlex. ChemImage Corp. v. Johnson & Johnson
8
Pittsburgh Post-Gazette. Pittsburgh Company Awarded $40 Million in Contract Dispute
9
Justia. ChemImage Corp. v. Johnson & Johnson, Findings of Fact and Conclusions of Law
10
USA Herald. J&J Unit Owes $76.6M for Ending AI Tissue Imaging Deal
11
Pittsburgh Post-Gazette. Pittsburgh Biotech Startup Ethicon ChemImage